Trials / Completed
CompletedNCT02448303
Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer
A Phase 2 Proof-of-Concept Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Non-small Cell Lung Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 74 (actual)
- Sponsor
- Acerta Pharma BV · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Pembrolizumab alone and in combination with acalabrutinib in subjects with advanced non-small cell lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pembrolizumab | |
| DRUG | Acalabrutinib |
Timeline
- Start date
- 2015-05-01
- Primary completion
- 2018-03-01
- Completion
- 2018-06-01
- First posted
- 2015-05-19
- Last updated
- 2019-09-12
- Results posted
- 2019-09-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02448303. Inclusion in this directory is not an endorsement.